PT - JOURNAL ARTICLE AU - Tatiana Luchnikova AU - Olga Prikhodko TI - Vitamin D as a marker of worsening of the course of pneumonia AID - 10.1183/13993003.congress-2020.2343 DP - 2020 Sep 07 TA - European Respiratory Journal PG - 2343 VI - 56 IP - suppl 64 4099 - http://erj.ersjournals.com/content/56/suppl_64/2343.short 4100 - http://erj.ersjournals.com/content/56/suppl_64/2343.full SO - Eur Respir J2020 Sep 07; 56 AB - The potential effect of vitamin D on the course of pulmonary infection is due to its ability to affect cellular and humoral immunity, thereby reducing the inflammatory processThe main aim of research to determine the content of vitamin D in patients with pneumonia and its degree of influence on the course of lung infection.Materials and Methods: The study involved 89 patients with moderate to severe pneumonia. Of these, 50 patients had moderate severity of community-acquired pneumonia, and 39 were severe. The comparison group consisted of 30 people without bronchopulmonary pathology.Research Results and Discussion: The average 25- (OH) D level in patients with lung infection was 18.63 ± 5.73, in the comparison group (without bronchopulmonary pathology) - 27.47 ± 3.65ng / ml (p < 0.001). In 66% of patients, vitamin D deficiency was detected, in 24% insufficient intake, in 10% the optimal content of vitamin D. Moreover, in patients with severe infectious diseases, vitamin D deficiency occurred in 88% of cases (p = 0.001).A relationship was found between the level of vitamin D and the etiology of the disease (r = -0.54, p = 0.0002). So patients with bacterial lung infection had a more pronounced deficiency of vitamin D, compared with pneumonia of viral etiology. We studied the level of vitamin D in patients with fatal outcome caused by pneumonia. All the dead had an extreme vitamin D deficiency of 6.45 ± 2.65 ng/ml. Vitamin D deficiency can be considered a marker of severe course and adverse outcome of lung infections. Vitamin D in patients with lung infection deserves special attention and needs a more detailed study in diseases of the bronchopulmonary system.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2343.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).